Free Trial

Galera Therapeutics (GRTX) Competitors

Galera Therapeutics logo
$0.03 +0.00 (+5.77%)
As of 07/8/2025 03:53 PM Eastern

GRTX vs. CYCC, TCRT, PMCB, CLDI, ORGS, APLM, SLXN, AIM, OMGA, and CELZ

Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Cyclacel Pharmaceuticals (CYCC), Alaunos Therapeutics (TCRT), Nuvilex (PMCB), Calidi Biotherapeutics (CLDI), Orgenesis (ORGS), Apollomics (APLM), Silexion Therapeutics (SLXN), AIM ImmunoTech (AIM), Omega Therapeutics (OMGA), and Creative Medical Technology (CELZ). These companies are all part of the "pharmaceutical products" industry.

Galera Therapeutics vs. Its Competitors

Galera Therapeutics (NASDAQ:GRTX) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cyclacel Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cyclacel Pharmaceuticals has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M-$0.35-0.08
Cyclacel Pharmaceuticals$40K132.72-$11.21M-$56.00-0.06

Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.

In the previous week, Cyclacel Pharmaceuticals had 13 more articles in the media than Galera Therapeutics. MarketBeat recorded 13 mentions for Cyclacel Pharmaceuticals and 0 mentions for Galera Therapeutics. Cyclacel Pharmaceuticals' average media sentiment score of 0.16 beat Galera Therapeutics' score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Galera Therapeutics Neutral
Cyclacel Pharmaceuticals Neutral

Galera Therapeutics' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
Cyclacel Pharmaceuticals N/A -3,648.09%-155.99%

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Comparatively, 96.9% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cyclacel Pharmaceuticals beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRTX vs. The Competition

MetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.08M$778.91M$5.47B$8.95B
Dividend YieldN/A4.84%5.25%4.04%
P/E Ratio-0.081.0926.9620.11
Price / SalesN/A230.52430.20119.79
Price / CashN/A23.4436.8257.86
Price / Book-0.016.137.985.56
Net Income-$59.08M-$27.85M$3.16B$248.40M
7 Day PerformanceN/A0.67%2.39%4.67%
1 Month PerformanceN/A8.48%2.18%6.64%
1 Year PerformanceN/A6.72%33.82%21.31%

Galera Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRTX
Galera Therapeutics
0.2751 of 5 stars
$0.03
+5.8%
N/A-78.9%$2.08MN/A-0.0830Gap Down
CYCC
Cyclacel Pharmaceuticals
0.7539 of 5 stars
$0.32
-2.5%
N/A-99.1%$7.65M$40K-0.0114Stock Split
TCRT
Alaunos Therapeutics
0.4899 of 5 stars
$4.52
-6.9%
N/A-20.5%$7.41M$10K-1.7840
PMCB
Nuvilex
0.8871 of 5 stars
$1.08
-1.4%
N/A-49.5%$7.37MN/A1.454Positive News
CLDI
Calidi Biotherapeutics
0.4661 of 5 stars
$0.23
-1.7%
N/A-79.3%$7.15M$50K0.0038News Coverage
Gap Up
ORGS
Orgenesis
N/A$1.48
-1.7%
N/AN/A$7.08M$662K0.00150News Coverage
Gap Down
APLM
Apollomics
0.3356 of 5 stars
$6.38
-2.8%
N/A-65.8%$7.01M$1.49M0.0045News Coverage
Positive News
Gap Down
SLXN
Silexion Therapeutics
N/A$0.81
-0.4%
$5.00
+519.6%
N/A$6.95MN/A0.00N/A
AIM
AIM ImmunoTech
1.6705 of 5 stars
$9.09
+5.1%
$275.00
+2,925.3%
-75.3%$6.95M$146K-19.3420Gap Up
OMGA
Omega Therapeutics
2.1196 of 5 stars
$0.13
-21.8%
$8.50
+6,700.0%
-93.0%$6.92M$8.10M-0.09120Gap Up
CELZ
Creative Medical Technology
N/A$2.65
-0.2%
N/A-24.6%$6.85M$10K-0.695Positive News

Related Companies and Tools


This page (NASDAQ:GRTX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners